XZXiangkai Zhao

Xiangkai Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiangkai Zhao has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Cheng Zhang

    State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research of MOE, NHC, CAMS and Shandong Province, Department of Cardiology, Qilu Hospital of Shandong University, China

    2 shared publications
  • Feng Xu

    Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan 250012, China

    2 shared publications
  • Yuguo Chen

    Department of Emergency Medicine, Qilu Hospital of Shandong University

    2 shared publications
  • Chang Pan

    Departments of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China (S.S., X. Zhang, H.Y., C.F., Y.G., X.L., S.C., K.Y., X. Zhao, C.P., F.X., Y.C.).

    1 shared publication
  • Chang Pan

    Department of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China

    1 shared publication
  • Cuiqin Fan

    Departments of Emergency Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China (S.S., X. Zhang, H.Y., C.F., Y.G., X.L., S.C., K.Y., X. Zhao, C.P., F.X., Y.C.).

    1 shared publication

Latest Publications

  • Open Access

    The Aldehyde Dehydrogenase 2 rs671 Variant Enhances Platelet Activation and Arterial Thrombosis

    by Song Sun, Xuan Zhang, Hongwei Yue, Cuiqin Fan, Yi Zhang, Yunyun Guo, Xingming Li, Sumei Cui, Kehui Yang, Xiangkai Zhao, et al.

    BACKGROUND: Acute myocardial infarction (AMI) caused by thrombosis is a major cause of mortality. A polymorphism in Aldh2 gene (rs671) is found in approximately 30% to 50% of East Asians, and it is a risk factor for AMI. This mutation impairs aldehyde dehydrogenase 2 (ALDH2) function, but the effect of ALDH2 on platelet activation and thrombosis is unknown. METHODS: Platelets were isolated from platelet-specific Aldh2 knockout ( Aldh2 -/- ) and ALDH2 E506K knock-in mice (which corresponds to human Aldh2 rs671 gene mutation), as well as from healthy human donors with the Aldh2 rs671. Arterial thrombosis was measured in a FeCl 3 -induced thrombosis mouse model. The efficacy of Alda-1, an ALDH2 activator, in mitigating thrombogenesis was measured in ALDH2 E506K mice. Using a murine model of myocardial infarction (MI) model, we analyzed the effects of platelet Aldh2 on micro-thrombosis and infarct expansion post-MI. In addition, we enrolled 118 patients of different Aldh2 rs671 genotypes (GG, GA, and AA) diagnosed with ST elevation myocardial infarction (STEMI) to analyze the association between rs671 genotype and platelet activation and thrombosis. RESULTS: Platelets from Aldh 2 -/- and ALDH2 E506K mice showed enhanced agonist induced aggregation, ATP release, integrin αIIbβ3 activation, P-selectin release, spreading, and clot retraction. Human platelets with the Aldh2 rs671 variant also exhibited increased activation. Mutation of Aldh2 or platelet-specific knockout of Aldh2 exacerbated thrombus formation in a mouse model of thrombosis. The ALDH2 activator, Alda-1, reduced thrombosis in ALDH2 E506K mice. We explored pathways mediating the effect of Aldh2 on platelet activation. We found that platelets lacking Aldh2 produced more reactive oxygen species (ROS) and less nitric oxide (NO) than wild-type platelets. Furthermore, platelets lacking Aldh2 are also more susceptible to activation by aldehydes. Additionally, platelets from mice lacking Aldh2 had increased elevated mitophagy and hyperactivity. ACAD10 mediated some of the effects of ALDH2 on mitophagy. Mice lacking Aldh2 had increased micro-thrombosis and myocardial infarct expansion. Finally, elevated platelet activation and thrombus markers were also observed in plasma from patients with STEMI patients who had the rs671 variant. CONCLUSIONS: The Aldh2 rs671 variant, which impairs ALDH2 function, increases platelet activation and thrombus formation in vivo through aldehyde accumulation and ROS buildup. Abnormal ACAD10 homeostasis might also contribute to this hyperactivity via enhancing platelet mitophagy. Our findings suggest the potential of ALDH2 as a novel antiplatelet target. Future studies are needed to explore the effects of more aggressive antiplatelet therapy for patients at risk of MI who carry the Aldh2 rs671 mutation.


  • Top Cited Papers

    The role of aldehyde dehydrogenase 2 in cardiovascular disease

    by Jian Zhang, Yunyun Guo, Xiangkai Zhao, Jiaojiao Pang, Chang Pan, Jiali Wang, Shujian Wei, Xiao Yu, Cheng Zhang, Yuguo Chen, et al.

    Aldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme involved in the detoxification of alcohol-derived acetaldehyde and endogenous aldehydes. The inactivating ALDH2 rs671 polymorphism, present in up to 8% of the global population and in up to 50% of the East Asian population, is associated with increased risk of cardiovascular conditions such as coronary artery disease, alcohol-induced cardiac dysfunction, pulmonary arterial hypertension, heart failure and drug-induced cardiotoxicity. Although numerous studies have attributed an accumulation of aldehydes (secondary to alcohol consumption, ischaemia or elevated oxidative stress) to an increased risk of cardiovascular disease (CVD), this accumulation alone does not explain the emerging protective role of ALDH2 rs671 against ageing-related cardiac dysfunction and the development of aortic aneurysm or dissection. ALDH2 can also modulate risk factors associated with atherosclerosis, such as cholesterol biosynthesis and HDL biogenesis in hepatocytes and foam cell formation and efferocytosis in macrophages, via non-enzymatic pathways. In this Review, we summarize the basic biology and the clinical relevance of the enzymatic and non-enzymatic, tissue-specific roles of ALDH2 in CVD, and discuss the future directions in the research and development of therapeutic strategies targeting ALDH2. A thorough understanding of the complex roles of ALDH2 in CVD will improve the diagnosis, management and prognosis of patients with CVD who harbour the ALDH2 rs671 polymorphism.